Fort Sheridan Advisors LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 2.6% during the first quarter, HoldingsChannel.com reports. The fund owned 7,318 shares of the biopharmaceutical company’s stock after buying an additional 188 shares during the quarter. Fort Sheridan Advisors LLC’s holdings in Gilead Sciences were worth $435,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors have also recently made changes to their positions in the stock. State Street Corp boosted its holdings in shares of Gilead Sciences by 4.0% during the 4th quarter. State Street Corp now owns 57,369,269 shares of the biopharmaceutical company’s stock valued at $4,165,583,000 after acquiring an additional 2,187,144 shares during the last quarter. Capital World Investors boosted its holdings in shares of Gilead Sciences by 15.4% during the 4th quarter. Capital World Investors now owns 42,681,624 shares of the biopharmaceutical company’s stock valued at $3,099,157,000 after acquiring an additional 5,705,315 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Gilead Sciences by 2.0% during the 4th quarter. Geode Capital Management LLC now owns 22,739,179 shares of the biopharmaceutical company’s stock valued at $1,647,123,000 after acquiring an additional 440,695 shares during the last quarter. Northern Trust Corp boosted its holdings in shares of Gilead Sciences by 0.4% during the 4th quarter. Northern Trust Corp now owns 14,538,441 shares of the biopharmaceutical company’s stock valued at $1,055,636,000 after acquiring an additional 60,475 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at about $950,911,000. Hedge funds and other institutional investors own 80.16% of the company’s stock.
Analyst Upgrades and Downgrades
A number of analysts have recently issued reports on the stock. Piper Sandler dropped their price target on shares of Gilead Sciences from $73.00 to $69.00 and set a “neutral” rating on the stock in a report on Monday, May 16th. Royal Bank of Canada increased their price objective on shares of Gilead Sciences from $76.00 to $77.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 12th. Cantor Fitzgerald assumed coverage on shares of Gilead Sciences in a research note on Tuesday, July 12th. They issued a “neutral” rating and a $70.00 price objective on the stock. Morgan Stanley increased their price objective on shares of Gilead Sciences from $63.00 to $65.00 and gave the stock an “equal weight” rating in a research note on Friday, July 15th. Finally, TheStreet cut shares of Gilead Sciences from a “b-” rating to a “c+” rating in a research note on Friday, July 1st. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and five have issued a buy rating to the company. According to MarketBeat, Gilead Sciences presently has an average rating of “Hold” and an average target price of $72.07.
Gilead Sciences Price Performance
Gilead Sciences Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 29th. Stockholders of record on Thursday, September 15th will be given a dividend of $0.73 per share. This represents a $2.92 annualized dividend and a dividend yield of 4.78%. The ex-dividend date of this dividend is Wednesday, September 14th. Gilead Sciences’s payout ratio is currently 89.02%.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.
- Get a free copy of the StockNews.com research report on Gilead Sciences (GILD)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.